Strongbridge Biopharma Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for RECORLEV® for the Treatment of Endogenous Cushing’s Syndrome
FDA has accepted the filing of the RECORLEV® (levoketoconazole) New Drug Application. Strongbridge Biopharma believes that this decision reflects the extensive clinical evidence in the NDA submissio ...